Form 8-K · Current Report · Filed 2026-01-07
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics Pharmaceuticals, Inc. announced a proposed public offering of 7,620,000 shares of its common stock with an option for underwriters to purchase up to an additional 1,143,000 shares. The offering, expected to close on January 8, 2026, aims to raise approximately $330.2 million, or $379.8 million if the option is fully exercised, after deducting underwriting discounts, commissions, and estimated offering expenses. The Company intends to use the net proceeds for commercial activities, research and development, and other general corporate purposes.
- Filer
- Crinetics Pharmaceuticals Inc. CRNX · NASDAQ
- Filed
- Accession
- 0001193125-26-006421
- CIK
- 0001658247
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$45.95
Next session
+15.9%
Since filing
+81.8%
Latest close
$83.52
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from CRNX reporting the same item, with the next session's move:
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Never miss another CRNX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.